Abstract
Adenosine influx by Trypanosoma brucei brucei P1 and P2 transporters was kinetically characterized. The P1 transporter displayed a higher affinity and capacity for adenosine (K m = 0.38 ± 0.10 μM,V max = 2.8 ± 0.4 pmol · 107 cells−1 · s−1) than the P2 transporter (K m = 0.92 ± 0.06 μM, V max = 1.12 ± 0.08 4 pmol · 107cells−1 · s−1). To formulate a structure-activity relationship for the interaction of adenosine with the transporters, a series of analogs were evaluated as potential inhibitors of adenosine transport, and theK i values were converted to binding energy. The P1 transporter was found to be selective inhibited by purine nucleosides (K i ∼ 1 μM for inosine and guanosine), but nucleobases and pyrimidines had little effect on P1-mediated transport. The P1 transporter appears to form hydrogen bonds with N3 and N7 of the purine ring as well as with the 3′ and 5′ hydroxyl groups of the ribose moiety, with apparent bond energies of 12.8 to 15.8 kJ/mol. The P2 transporter, in contrast, had high-affinity (K i = 0.2–4 μM) for 6-aminopurines, including adenine, 2′-deoxyadenosine, and tubercidin, but not for any oxopurines. The main interaction of adenosine with the P2 transporter is suggested to be via hydrogen bonds to N1 and the 6-amino group. Additional π-π interactions of the purine ring and electrostatic interactions with N9 may also be important. The predicted substrate recognition motif of P2, but not of P1, corresponds to parts of the melaminophenylarsenical and diamidine molecules, confirming the potent inhibition observed with these trypanocides for P2-mediated adenosine transport (K i = 0.4–2.4 μM).
Footnotes
- Received April 1, 1999.
- Accepted August 25, 1999.
-
Send reprint requests to: Dr. Simon M. Jarvis, Research School of Biosciences, University of Kent at Canterbury, Canterbury, Kent CT2 7NJ, UK. E-mail: S.M.Jarvis{at}ukc.ac.uk
-
↵1 Current address: Institute of Biomedical and Life Sciences, Division of Infection and Immunity, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK.
-
This work was supported by the Wellcome Trust (Grant 041181/Z/94).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|